vx has been researched along with irinotecan in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Agnusdei, M; Belinskaya, T; Borriello, M; Brindisi, M; Butini, S; Campiani, G; Catalanotti, B; Fattorusso, C; Fiorini, I; Gemma, S; Nacci, V; Novellino, E; Panico, A; Persico, M; Ros, S; Saxena, A | 1 |
| Barnes, CS; Charlton, P; Doroshow, JH; Guha, R; Jones, J; Jossé, R; Martin, SE; Morris, J; Ormanoglu, P; Pfister, TD; Pollard, JR; Pommier, Y; Reaper, PM | 1 |
2 other study(ies) available for vx and irinotecan
| Article | Year |
|---|---|
Exploiting protein fluctuations at the active-site gorge of human cholinesterases: further optimization of the design strategy to develop extremely potent inhibitors.
Topics: Acetylcholinesterase; Binding Sites; Butyrylcholinesterase; Cholinesterase Inhibitors; Computational Biology; Crystallography, X-Ray; Drug Design; Humans; Models, Molecular; Protein Conformation; Structure-Activity Relationship; Tacrine | 2008 |
ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses.
Topics: Ataxia Telangiectasia Mutated Proteins; Camptothecin; Cell Line, Tumor; Checkpoint Kinase 1; DNA Damage; DNA Replication; DNA Topoisomerases, Type I; Histones; HT29 Cells; Humans; Irinotecan; Organothiophosphorus Compounds; Phosphorylation; Protein Kinases; Pyrazines; Replication Origin; Single-Cell Analysis; Sulfones; Topoisomerase I Inhibitors; Topotecan | 2014 |